Abbott, BioCurex Enter Into Agreement for RECAF Technology

Abbott and BioCurex announced they have entered into a licensing agreement for BioCurex's RECAF material and technology. The receptor for alpha-fetoprotein, RECAF has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. RECAF is found on malignant cells from a variety of cancer cell types but is absent in most normal and benign cells.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/03-29-2005/0003288440&EDATE=)